Aclaris Therapeutics, Inc. (ACRS): Total Assets
$160.46M
As of 2025-12-31
$179.69M
As of 2026-06-30
-14.3%
3-year compound annual growth
+17.8%
5-year compound annual growth
+5.5%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $160.46M | -27.2% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $220.33M | +11.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $197.41M | -22.5% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $254.60M | +1.3% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $251.21M | +254.9% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $70.78M | -28.0% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $98.30M | -64.3% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $275.57M | +13.2% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $243.51M | +38.3% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $176.09M | +87.2% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $94.08M | +441.4% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $17.38M | n/a | 2016-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $160.46M | -27.2% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $49.95M | +12.6% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $56.75M | -43.0% |
| Adagene Inc. (ADAG) | 2025-12-31 | $78.26M | -12.3% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $633.16M | -20.7% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $5.71B | +5.0% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $150.93M | +63.8% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $150.83M | +114.5% |
| Immunome Inc. (IMNM) | 2025-12-31 | $683.19M | +184.4% |
Compare ACRS, COYA, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗